Prelude Therapeutics Incorporated (PRLD) — Financial statements
Income statement, balance sheet, and cash flow for Prelude Therapeutics Incorporated — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 12↑73.4% | 7 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 2 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 10↑49.0% | 7 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 94↓20.1% | 118↑14.1% | 103↑11.3% | 93↑7.0% | 87 | |
| General & Administrative Expenses | 22↓22.0% | 29↓0.6% | 29↓5.8% | 31↑13.7% | 27 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 22↓22.0% | 29↓0.6% | 29↓5.8% | 31↑13.7% | 27 | |
| Other Expenses | -2 | 0.00↑100.0% | -0.00 | 0.00 | 0.00 | |
| Operating Expenses | 115↓21.6% | 147↑10.9% | 132↑7.1% | 124↑8.6% | 114 | |
| Total Costs & Expenses | 117↓20.5% | 147↑10.9% | 132↑7.1% | 124↑8.6% | 114 | |
| Operating Results | ||||||
| Operating Income | -105↑25.2% | -140↓5.6% | -132↓7.1% | -124↓8.6% | -114 | |
| Depreciation & Amortization | 2↓3.4% | 2↑51.6% | 1↓11.7% | 1↑44.7% | 0.92 | |
| EBITDA | -103↑25.4% | -138↓5.2% | -131↓7.3% | -122↓8.3% | -113 | |
| EBIT | -105↑25.2% | -140↓5.6% | -132↓7.1% | -124↓8.6% | -114 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 5↓59.6% | 13↑20.1% | 10↑28.9% | 8↑297.0% | 2 | |
| Income Before Tax | -99↑21.8% | -127↓4.4% | -122↓5.5% | -115↓3.4% | -112 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -99↑21.8% | -127↓4.4% | -122↓5.5% | -115↓3.4% | -112 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -99↑21.8% | -127↓4.4% | -122↓5.5% | -115↓3.4% | -112 | |
| Bottom-Line Net Income | -99↑21.8% | -127↓4.4% | -122↓5.5% | -115↓3.4% | -112 | |
| EPS (Basic) | -1.29↑23.2% | -1.68↑16.8% | -2.02↑11.0% | -2.27↑2.6% | -2.33 | |
| EPS (Diluted) | -1.29↑23.2% | -1.68↑16.8% | -2.02↑11.0% | -2.27↑2.6% | -2.33 | |
| Weighted Average Shares | 77↑1.5% | 76↑25.6% | 60↑27.4% | 47↓0.5% | 48 | |
| Weighted Average Diluted Shares | 77↑1.5% | 76↑25.6% | 60↑27.4% | 47↓0.5% | 48 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.